➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
AstraZeneca
Moodys
Colorcon

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Navitoclax

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Navitoclax?

Navitoclax is an investigational drug.

There have been 19 clinical trials for Navitoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on September 14th 2020.

The most common disease conditions in clinical trials are Primary Myelofibrosis, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are AbbVie, National Cancer Institute (NCI), and Genentech, Inc.

There are one hundred and seventy-six US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Navitoclax
TitleSponsorPhase
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisAbbViePhase 3
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisAbbViePhase 1
Safety, Efficacy, and Assessment of Change in Spleen Volume Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet in Adult Participants With Relapsed/Refractory MyelofibrosisAbbViePhase 3

See all Navitoclax clinical trials

Clinical Trial Summary for Navitoclax

Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax

See all Navitoclax clinical trials

US Patents for Navitoclax

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Navitoclax   Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Start Trial
Navitoclax   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
Navitoclax   Start Trial Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)   Start Trial
Navitoclax   Start Trial Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors AbbVie Inc. (North Chicago, IL)   Start Trial
Navitoclax   Start Trial Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Navitoclax

Drugname Country Document Number Estimated Expiration Related US Patent
Navitoclax Canada CA2922341 2033-08-28   Start Trial
Navitoclax European Patent Office EP3038618 2033-08-28   Start Trial
Navitoclax World Intellectual Property Organization (WIPO) WO2015031608 2033-08-28   Start Trial
Navitoclax Argentina AR102649 2034-11-14   Start Trial
Navitoclax Australia AU2015347015 2034-11-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
AstraZeneca
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.